Urological Science

EDITORIAL
Year
: 2020  |  Volume : 31  |  Issue : 1  |  Page : 3-

Immuno-oncology: The frontier in caring urological patients


Stephen Shei-Dei Yang 
 Editor-in-Chief, Urological Science; Department of Urology, Taipei Tzu Chi Hospital, New Taipei; School of Medicine, Buddhist Tzu Chi University, Hualien, Taiwan

Correspondence Address:
Dr. Stephen Shei-Dei Yang
Department of Urology, Taipei Tzu Chi Hospital and Buddhist Tzu Chi University, New Taipei City
Taiwan




How to cite this article:
Yang SS. Immuno-oncology: The frontier in caring urological patients.Urol Sci 2020;31:3-3


How to cite this URL:
Yang SS. Immuno-oncology: The frontier in caring urological patients. Urol Sci [serial online] 2020 [cited 2020 Oct 21 ];31:3-3
Available from: https://www.e-urol-sci.com/text.asp?2020/31/1/3/278871


Full Text



Happy New Year!

Wish all readers a healthy and prosperous New Golden Mouse Year!

Immunotherapy, especially immune checkpoint blockade treatment, has changed the landscape of anticancer therapy in many fields of cancer treatment. The programmed cell death-1/programmed cell death-ligand 1 blockade alone has resulted in better treatment outcomes than conventional therapies, such as chemotherapy and targeted therapy in advanced urothelial carcinoma and renal cell carcinoma (RCC). In this issue, Guo JC and Lin CC presented “Rational combination with an immunotherapy backbone in genitourinary cancers.” This is a must read for all urologists, particularly for those under training. Hsueh FJ and Tsai YC summarized the “current and future aspect of immunotherapy for advanced renal cell carcinoma.” Through this article, one may learn how to use immunotherapy in advanced RCC and keep in pace with the development of immuno-oncology in genitourinary cancers.

Inoue S reported the “Prevalence of hand joint symptoms in androgen deprivation therapy among the Japanese patients with prostate cancer.” He found that joint pain, numbness, and muscle weakness, assessed by questionnaire, were more common in patients receiving androgen deprivation therapy than those hormone-naïve prostate cancer patients. Inoue S did analysis on “Factors affecting hospital stay in patients aged >65 years who underwent urological intervention: A single-center retrospective study.” According the retrospective data, he concluded that only robotic-assisted radical prostatectomy significantly improved voiding symptom as compared to laparoscopic and open radical prostatectomy procedures. However, none of the procedures changed storage symptom in the 1-year follow-up.

Bombaci E investigated the “Factors affecting hospital stay in patients aged >65 years who underwent urological intervention: A single-center retrospective study.” Except older age, the following risk factors are suggested to be evaluated and managed before urological intervention: surgical method, duration of surgery, anesthesia method, presence of a comorbid disease, ASA Physical Status, preoperative values of blood serum albumin and hemoglobin, presence of infection, and intensive care hospitalization.